Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383:1413–1424

Article  PubMed  CAS  Google Scholar 

McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995–2008

Article  PubMed  CAS  Google Scholar 

Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G et al (2020) SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials. Lancet 396:819–829

Article  PubMed  Google Scholar 

Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF et al (2022) SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet 400(10354):757–767

Article  PubMed  CAS  Google Scholar 

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al (2022) 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 79(17):1757–1780

Article  PubMed  Google Scholar 

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M et al (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599–3726

Article  PubMed  CAS  Google Scholar 

Lahnwong C, Palee S, Apaijai N, Sriwichaiin S, Kerdphoo S, Jaiwongkam T et al (2020) Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury. Cardiovasc Diabetol 19:91

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tanajak P, Sa-Nguanmoo P, Sivasinprasasn S, Thummasorn S, Siri-Angkul N, Chattipakorn SC et al (2018) Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury. J Endocrinol 236:69–84

Article  PubMed  CAS  Google Scholar 

Lee T-M, Chang N-C, Lin S-Z (2017) Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med 104:298–310

Article  PubMed  CAS  Google Scholar 

Yurista SR, Silljé HHW, Oberdorf-Maass SU, Schouten EM, PavezGiani MG, Hillebrands JL et al (2019) Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail 21:862–873

Article  PubMed  CAS  Google Scholar 

Wang M, Liu X, Ding B, Lu Q, Ma J (2024) SGLT2 inhibitor dapagliflozin alleviates cardiac dysfunction and fibrosis after myocardial infarction by activating PXR and promoting angiogenesis. Biomed Pharmacother 177:116994

Article  PubMed  CAS  Google Scholar 

Zhang X, Sun G, Li Z, Gao W, Tan W, Liu J et al (2024) Effectiveness of sodium-glucose cotransporter 2 inhibitors in patients with acute myocardial infarction with or without type 2 diabetes: a systematic review and meta-analysis. J Cardiovasc Pharmacol 84(1):18–25

Article  PubMed  CAS  Google Scholar 

Idowu A, Adebolu O, Wattanachayakul P, Obomanu E, Shah S, Lo KB, Pressman G (2024) Cardiovascular outcomes of sodium-glucose Co-transporter 2 inhibitors use after myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. Curr Probl Cardiol 49(8):102648

Article  PubMed  Google Scholar 

Dayem KA, Younis O, Zarif B, Attia S, AbdelSalam A (2023) Impact of dapagliflozin on cardiac function following anterior myocardial infarction in non-diabetic patients - DACAMI (a randomized controlled clinical trial). Int J Cardiol 379:9–14

Article  PubMed  Google Scholar 

von Lewinski D, Kolesnik E, Tripolt NJ, Pferschy PN, Benedikt M, Wallner M et al (2022) Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J 43(41):4421–4432

Article  Google Scholar 

Butler J, Jones WS, Udell JA, Anker SD, Petrie MC, Harrington J et al (2024) Empagliflozin after acute myocardial infarction. N Engl J Med 390(16):1455–1466

Article  PubMed  CAS  Google Scholar 

James S, Erlinge D, Storey RF, McGuire DK, de Belder M, Eriksson N et al (2024) Dapagliflozin in myocardial infarction without diabetes or heart failure. NEJM Evid 3(2):EVIDoa2300286

Article  PubMed  Google Scholar 

Shimizu W, Kubota Y, Hoshika Y, Mozawa K, Tara S, Tokita Y et al (2020) Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial. Cardiovasc Diabetol 19(1):148

Article  PubMed  PubMed Central  CAS  Google Scholar 

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane Handbook for Systematic Reviews of Interventions Version 6.3. The Cochrane Collaboration; 2022. Available at: www.handbook.cochrane.org. Accessed 14 June 2024

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71

Article  PubMed  PubMed Central  Google Scholar 

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898

Article  PubMed  Google Scholar 

Lau J, Ioannidis JPA, Terrin N, Schmid CH, Olkin I (2006) The case of the misleading funnel plot. BMJ 333(7568):597–600

Article  PubMed  PubMed Central  Google Scholar 

Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S et al (2004) Grading quality of evidence and strength of recommendations. BMJ 328:1490

Article  PubMed  Google Scholar 

Talha KM, Anker SD, Butler J (2023) SGLT-2 inhibitors in heart failure: a review of current evidence. Int J Heart Fail 5(2):82–90

Article  PubMed  PubMed Central  Google Scholar 

McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995–2008

Article  PubMed  CAS  Google Scholar 

Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlávek J et al (2020) Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA 323:1353–1368

Article  PubMed  PubMed Central  CAS  Google Scholar 

Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF et al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387(12):1089–1098

Article  PubMed  Google Scholar 

Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385(16):1451–1461

Article  PubMed  CAS  Google Scholar 

Kwon O, Myong JP, Lee Y, Choi YJ, Yi JE, Seo SM et al (2023) Sodium-glucose cotransporter-2 inhibitors after acute myocardial infarction in patients with type 2 diabetes: a population-based investigation. J Am Heart Assoc 12(14):e027824

Article  PubMed  PubMed Central  Google Scholar 

Mao L, Cai D, Chi B, Xiao T, Zou A, Wang Y et al (2023) Dapagliflozin reduces risk of heart failure rehospitalization in diabetic acute myocardial infarction patients: a propensity score-matched analysis. Eur J Clin Pharmacol 79(7):915–926

Article  PubMed  PubMed Central  CAS  Google Scholar